Single nucleotide variations of the human GR gene manifested as pathologic mutations or polymorphisms

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

The human genome contains numerous single nucleotide variations, and the human glucocorticoid receptor (GR) gene harbors;450 of these genetic changes. Among them, extremely rare, nonsynonymous variants, known as pathologic GR gene mutations, develop a characteristic pathologic condition, familial/sporadic generalized glucocorticoid resistance syndrome, by replacing the amino acids critical for GR protein structure and functions, whereas others, known as pathologic polymorphisms, develop mild manifestations recognized mainly at population bases by changing the GR activities slightly. Recent progress on the structural analysis to the GR protein and subsequent computer-based structural simulation revealed details of the molecular defects caused by such pathologic GR gene mutations, including their impact on the receptor interaction to ligands, nuclear receptor coactivators (NCoAs) or DNA glucocorticoid response elements (GREs). Indeed, those found in the GR ligand-binding domain significantly damage protein structure of the ligandbinding pocket and/or the activation function-2 transactivation domain and change their molecular interaction to glucocorticoids or the LxxLL signature motif of NCoAs. Two mutations found in GR DNA-binding domain also affect interaction of the mutant receptors to GRE DNA by affecting the critical amino acid for the interaction or changing local hydrophobic circumstance. In this review, I discuss recent findings on the structural simulation of the pathologic GR mutants in connection to their functional and clinical impacts, along with a brief explanation to recent research achievement on the GR polymorphisms.

Original languageEnglish
Pages (from-to)2506-2519
Number of pages14
JournalEndocrinology
Volume159
Issue number7
DOIs
Publication statusPublished - 1 Jul 2018

Fingerprint

Glucocorticoid Receptors
Nucleotides
Mutation
Genes
Nuclear Receptor Coactivators
Response Elements
Glucocorticoids
DNA
Ligands
Amino Acids
Proteins
Human Genome
Transcriptional Activation

ASJC Scopus subject areas

  • Endocrinology

Cite this

Single nucleotide variations of the human GR gene manifested as pathologic mutations or polymorphisms. / Kino, Tomoshige.

In: Endocrinology, Vol. 159, No. 7, 01.07.2018, p. 2506-2519.

Research output: Contribution to journalReview article

@article{983b9020107247febef1cda348244adb,
title = "Single nucleotide variations of the human GR gene manifested as pathologic mutations or polymorphisms",
abstract = "The human genome contains numerous single nucleotide variations, and the human glucocorticoid receptor (GR) gene harbors;450 of these genetic changes. Among them, extremely rare, nonsynonymous variants, known as pathologic GR gene mutations, develop a characteristic pathologic condition, familial/sporadic generalized glucocorticoid resistance syndrome, by replacing the amino acids critical for GR protein structure and functions, whereas others, known as pathologic polymorphisms, develop mild manifestations recognized mainly at population bases by changing the GR activities slightly. Recent progress on the structural analysis to the GR protein and subsequent computer-based structural simulation revealed details of the molecular defects caused by such pathologic GR gene mutations, including their impact on the receptor interaction to ligands, nuclear receptor coactivators (NCoAs) or DNA glucocorticoid response elements (GREs). Indeed, those found in the GR ligand-binding domain significantly damage protein structure of the ligandbinding pocket and/or the activation function-2 transactivation domain and change their molecular interaction to glucocorticoids or the LxxLL signature motif of NCoAs. Two mutations found in GR DNA-binding domain also affect interaction of the mutant receptors to GRE DNA by affecting the critical amino acid for the interaction or changing local hydrophobic circumstance. In this review, I discuss recent findings on the structural simulation of the pathologic GR mutants in connection to their functional and clinical impacts, along with a brief explanation to recent research achievement on the GR polymorphisms.",
author = "Tomoshige Kino",
year = "2018",
month = "7",
day = "1",
doi = "10.1210/en.2017-03254",
language = "English",
volume = "159",
pages = "2506--2519",
journal = "Endocrinology",
issn = "0013-7227",
publisher = "The Endocrine Society",
number = "7",

}

TY - JOUR

T1 - Single nucleotide variations of the human GR gene manifested as pathologic mutations or polymorphisms

AU - Kino, Tomoshige

PY - 2018/7/1

Y1 - 2018/7/1

N2 - The human genome contains numerous single nucleotide variations, and the human glucocorticoid receptor (GR) gene harbors;450 of these genetic changes. Among them, extremely rare, nonsynonymous variants, known as pathologic GR gene mutations, develop a characteristic pathologic condition, familial/sporadic generalized glucocorticoid resistance syndrome, by replacing the amino acids critical for GR protein structure and functions, whereas others, known as pathologic polymorphisms, develop mild manifestations recognized mainly at population bases by changing the GR activities slightly. Recent progress on the structural analysis to the GR protein and subsequent computer-based structural simulation revealed details of the molecular defects caused by such pathologic GR gene mutations, including their impact on the receptor interaction to ligands, nuclear receptor coactivators (NCoAs) or DNA glucocorticoid response elements (GREs). Indeed, those found in the GR ligand-binding domain significantly damage protein structure of the ligandbinding pocket and/or the activation function-2 transactivation domain and change their molecular interaction to glucocorticoids or the LxxLL signature motif of NCoAs. Two mutations found in GR DNA-binding domain also affect interaction of the mutant receptors to GRE DNA by affecting the critical amino acid for the interaction or changing local hydrophobic circumstance. In this review, I discuss recent findings on the structural simulation of the pathologic GR mutants in connection to their functional and clinical impacts, along with a brief explanation to recent research achievement on the GR polymorphisms.

AB - The human genome contains numerous single nucleotide variations, and the human glucocorticoid receptor (GR) gene harbors;450 of these genetic changes. Among them, extremely rare, nonsynonymous variants, known as pathologic GR gene mutations, develop a characteristic pathologic condition, familial/sporadic generalized glucocorticoid resistance syndrome, by replacing the amino acids critical for GR protein structure and functions, whereas others, known as pathologic polymorphisms, develop mild manifestations recognized mainly at population bases by changing the GR activities slightly. Recent progress on the structural analysis to the GR protein and subsequent computer-based structural simulation revealed details of the molecular defects caused by such pathologic GR gene mutations, including their impact on the receptor interaction to ligands, nuclear receptor coactivators (NCoAs) or DNA glucocorticoid response elements (GREs). Indeed, those found in the GR ligand-binding domain significantly damage protein structure of the ligandbinding pocket and/or the activation function-2 transactivation domain and change their molecular interaction to glucocorticoids or the LxxLL signature motif of NCoAs. Two mutations found in GR DNA-binding domain also affect interaction of the mutant receptors to GRE DNA by affecting the critical amino acid for the interaction or changing local hydrophobic circumstance. In this review, I discuss recent findings on the structural simulation of the pathologic GR mutants in connection to their functional and clinical impacts, along with a brief explanation to recent research achievement on the GR polymorphisms.

UR - http://www.scopus.com/inward/record.url?scp=85050990355&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050990355&partnerID=8YFLogxK

U2 - 10.1210/en.2017-03254

DO - 10.1210/en.2017-03254

M3 - Review article

C2 - 29762667

AN - SCOPUS:85050990355

VL - 159

SP - 2506

EP - 2519

JO - Endocrinology

JF - Endocrinology

SN - 0013-7227

IS - 7

ER -